An official website of the United States government
Home
This neoplasm is not reportable.
Name
EBV-positive mucocutaneous ulcer (EBVMCU)
ICD-O-3 Morphology
9680/1: EBV-positive mucocutaneous ulcer
Effective
2021 and later
Reportability
This neoplasm is not reportable
Primary Site(s)
No primary site specified
This hematopoietic disease is not reportable for the U.S. except for primary sites C700-C729, C751-C753.
Canada, refer to your specific province for reportability requirements.
Most common sites: skin and mucosal sites, including the oral mucosa, tonsils, palate, and gastrointestinal tract
Canada, refer to your specific province for reportability requirements.
Most common sites: skin and mucosal sites, including the oral mucosa, tonsils, palate, and gastrointestinal tract
Abstractor Notes
EBV-positive mucocutaneous ulcer (EBVMCU) is part of the Mature B-cell neoplasms lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B15)
EBVMCU involves the skin and mucosal sites, including the oral mucosa, tonsils, palate, and gastrointestinal tract.
Often presents as a well-circumscribed, often painful ulcer in mucosal or cutaneous sites.
EBVMCU involves the skin and mucosal sites, including the oral mucosa, tonsils, palate, and gastrointestinal tract.
Often presents as a well-circumscribed, often painful ulcer in mucosal or cutaneous sites.
Definition
EBV-positive mucocutaneous ulcer (EBVMCU) is a lymphoproliferative disorder (LPD) with a polymorphous lymphoid infiltrate including EBV-positive atypical large B cells and/or HRS-like cells, which typically involves mucosal and cutaneous sites in patients with immune deficiency/dysregulation (IDD). (WHO 5th edition)
Transformations to
This data item does not apply
Corresponding ICD-10 Codes (Cause of Death codes only)
D47.7 Other specified neoplasms of uncertain or unknown behavior of lymphoid, hematopoietic, and related tissue
Corresponding ICD-10-CM Codes (U.S. only)
D47.Z9 Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue (effective October 01, 2015)
Sources
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024. (WHO classification of tumours series, 5th ed.; vol. 11). https://publications.iarc.who.int/637.
Section: Lymphoid proliferations and lymphomas associated with immune deficiency and disregulation
Pages: Part B: 565-567
Section: Lymphoid proliferations and lymphomas associated with immune deficiency and disregulation
Pages: Part B: 565-567
International Classification of Diseases for Oncology, 3rd edition (including revisions). Geneva: World Health Organization, 2001, 2011, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
